THE FUTURE OF
BIO-TECHNOLOGY
ABOUT
NUMERAL XII
Numeral XII is an innovation-driven, growth-oriented investment holding group with a core focus on biotechnology.
Our mission is to advance human health and longevity by acquiring, supporting, and accelerating pioneering businesses in the BioTech space including stem cell therapy, genetic research, and regenerative medicine.
With a vision to become a global leader in medical innovation, we work closely with our portfolio companies to provide deep operational expertise, strategic capital, and access to transformative technologies.
While biotechnology forms the cornerstone of our current growth strategy, Numeral XII builds on a strong legacy in financial technology and inclusive finance. Our FinTech capabilities continue to play a vital role in expanding access to capital, driving operational efficiency, and supporting scalable, tech-enabled solutions across our portfolio.
Through a diversified approach that spans biotech, FinTech, and agro-processing, Numeral XII offers integrated support across legal, corporate finance, IT infrastructure, HR, and marketing — enabling our businesses to innovate faster, scale smarter, and expand globally. We are actively pursuing opportunities across Africa, Dubai, and other emerging markets.
At Numeral XII, we don’t just invest in companies — we partner for progress, empowering bold ideas that change lives.
